$14.51 $0.24 per serving
Product analysis
Boswellia Resin Extract may support joint comfort, but its preparation is not identified as one of those with the clearest supporting evidence. The expected benefit is therefore uncertain.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality40
Boswellic acid is identified, but the extract quality cannot be judged confidently. Differing quantity declarations also prevent a reliable combined amount.
Ingredient Transparency100
An amount and the boswellic acid form are stated. Those details help identify the ingredient without fully establishing how its quantity declarations relate.
Value For Money40
Value for the boswellia content remains uncertain. Differing quantity declarations prevent a reliable cost comparison based on a combined amount.
Customer Satisfaction82
Customer feedback is favorable across a substantial review pool. Those opinions do not establish equivalence to specific boswellia preparations.
Product Focus62
The single ingredient keeps the formula focused on boswellia supplementation. Joint comfort is a plausible use, but benefits from particular preparations cannot be assumed for this extract.
- Format
Capsule - Container
- 60 Capsule(s)
- Per serving
- $0.24
- Customer rating
- 4.6 · 2,182 ratings
Goals
Impact
High effect
Boswellia · 70 mg
Boswellia has limited evidence for improving knee osteoarthritis symptoms with specific 5-Loxin and Aflapin preparations. This product does not establish equivalence to those preparations, so its material cannot inherit their clinical results. Symptom relief in that setting also does not establish broad systemic inflammation reduction.
How this product is rated for Inflammation
Ingredient fit91
Boswellia provides the main relevant connection. The amount findings are partial rather than a confirmed clinical dose.
Goal fit
Boswellia supplies the main relevant ingredient connection.
Dose adequacy
Known eligible amounts receive partial comparison recognition; unresolved amounts cannot establish an additional dose contribution.
Pathways17
The strongest retained connection concerns cox and lox enzyme inhibition; this identifies a pathway link rather than proven clinical relief.
Depth
The strongest retained connection concerns cox and lox enzyme inhibition; this identifies a pathway link rather than proven clinical relief.
Breadth
No pathway reaches the saved coverage threshold.
Evidence35
Boswellia provides the strongest retained evidence connection, with the population and outcome limitations described above.
Evidence strength
Boswellia provides the strongest retained evidence connection, with the population and outcome limitations described above.
Studied preparation
The Boswellia material is unidentified and does not establish equivalence to a studied branded preparation.
Formulation logic100
No unmet required partner or configured conflict was identified. Meeting amount criteria does not establish added benefit from combining ingredients.
Partner coverage
No unmet required partner was identified for the retained ingredients; their combination does not establish extra benefit.
Conflicts
No configured ingredient conflict was identified in the supplied findings.
Effective doses
Eligible ingredients meet the saved amount threshold; this is not proof of an effective treatment dose.
Impact
Moderate effect
Boswellia · 70 mg
Boswellia at 420 mg is relevant to joint comfort through inflammation-related processes. Small, short studies suggest symptom support for particular preparations, but the extract here is not identified as the studied preparation, so the findings apply only partly.
How this product is rated for Joint Health
Ingredient fit97
The relevant ingredients are a clear focus of the formula. The assessed amounts fully meet the saved comparison benchmarks.
Goal fit
The relevant ingredients are a clear focus of the formula.
Dose adequacy
The assessed amounts fully meet the saved comparison benchmarks.
Pathways40
The strongest assessed area is inflammation control, with substantial coverage. One assessed area reaches the threshold for substantial coverage.
Depth
The strongest assessed area is inflammation control, with substantial coverage.
Breadth
One assessed area reaches the threshold for substantial coverage.
Evidence30
Boswellia provides the strongest evidence contribution among the assessed ingredients, with important limits on specific joint-comfort benefits. The assessed ingredients do not match the recognized trial preparations.
Evidence strength
Boswellia provides the strongest evidence contribution among the assessed ingredients, with important limits on specific joint-comfort benefits.
Studied preparation
The assessed ingredients do not match the recognized trial preparations.
Formulation logic100
The assessed ingredients can contribute independently or have their required partner. No configured ingredient conflict was matched in the supplied assessment. All ingredients included in this check reach its minimum amount threshold.
Partner coverage
The assessed ingredients can contribute independently or have their required partner.
Conflicts
No configured ingredient conflict was matched in the supplied assessment.
Effective doses
All ingredients included in this check reach its minimum amount threshold.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
standardized Boswellia extract (Boswelic Acid) | 350 mg | |
Boswellia powder | 70 mg |
Boswellia (Boswelic Acid) · 350 mg OverallScore72
A serving lists 420 mg of boswellia in two portions: 350 mg with 65% boswellic acids and 70 mg without a recorded percentage. The saved facts list 227.5 mg of boswellic acids for the first portion, while the second portion’s concentration is unknown.
How this ingredient is rated
Composition and Label Disclosure83
The 350 mg portion specifies 65% boswellic acids; no acid percentage is recorded for the separate 70 mg portion.
Marker and Preparation Disclosure
The 350 mg portion specifies 65% boswellic acids; no acid percentage is recorded for the separate 70 mg portion.
Composition and Label Disclosure60
The two portions are individually listed as 350 mg and 70 mg; a boswellic acid percentage and 227.5 mg of acids are recorded for the first.
Boswellia Amount and Marker Disclosure
The two portions are individually listed as 350 mg and 70 mg; a boswellic acid percentage and 227.5 mg of acids are recorded for the first.
Commercial Price and Usability
No price rule was evaluated.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Clinical Benefits of Boswellia Serrata (BOSMAX®) in Early Knee Osteoarthritis: A Randomized, Placebo-Controlled, Double-Blind Study.
- A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee.
- Boswellic Acids Improve Clinical Cognitive Scores and Reduce Systemic Inflammation in Patients with Mild to Moderate Alzheimer's Disease.
- A Standardized Boswellia serrata Extract Improves Knee Joint Function and Cartilage Morphology in Human Volunteers with Mild to Moderate Osteoarthritis in a Randomized Placebo-Controlled Study.
- A standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days-a double-blind, randomized, three-arm, parallel-group, multi-center, placebo-controlled trial.
- Oral herbal therapies for treating osteoarthritis.
- Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study.
- A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee.